Adnexus Therapeutics Files Registration Statement for Proposed Initial Public Offering.WALTHAM, Mass. -- Adnexus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the proposed initial public offering of its common stock. All shares in the offering will be sold by Adnexus. The book-running managers of the proposed offering will be Lehman Brothers and UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Securities LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control , and Cowen and Company and Lazard Freres & Co LLC will serve as co-managers. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Once available, a preliminary prospectus Preliminary Prospectus A first draft registration statement filed by a firm prior to proceeding with an initial public offering of securities. The document, filed with the Securities & Exchange Commission, is intended to provide pertinent information to prospective shareholders relating to these securities may be obtained by contacting the prospectus department at: Lehman Brothers Inc., c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717 (Fax: 631-254-7140; Email: qiana.smith@broadridge.com), or UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY 10171 (Tel: 212-821-3000). About Adnexus Therapeutics Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of a new class of drugs, Adnectins. Adnexus' first product candidate, Angiocept (CT-322), is in Phase 1 clinical development in oncology in the United States. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that enables rapid optimization of protein therapeutics. The company is funded by five leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] : Atlas Venture, Flagship Ventures, Polaris Venture Partners, Venrock, and HBM HBM Human Body Model HBM Human Brain Mapping HBM Hottinger Baldwin Messtechnik GmbH (German company) HBM High Bone Mass HBM Hybrid Bilayer Membrane HBM Humming Bird Medal HBM Her/His Britannic Majesty BioVentures. Adnectin[TM], Adnexus[TM] Therapeutics and PROfusion[TM] are trademarks of Adnexus[TM] Therapeutics, Inc. Adnexus(SM) Therapeutics is a service mark of Adnexus[TM] Therapeutics. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion